title: Maintenance of target hemoglobin level in stable hemodialysis patients constitutes a theoretical task: a historical prospective study.
abstract: Maintenance of target hemoglobin (Hb) values in hemodialysis patients treated with erythropoiesis-stimulating agents (ESAs) remains difficult. We examined Hb variability in the clinical setting in hemodialysis patients. Hemodialysis patients treated with ESAs who maintained the recommended Hb range of 11-13 g per 100 ml over 3 months and were not admitted to hospital, did not require transfusion, and did not experience any major clinical event during this period were followed prospectively for 1 year. Anemia events, Hb variation events (any value out of +/-1.5 g per 100 ml of the median Hb level in the total follow-up period for the individual patient), risk factors for anemia, and Hb variation events were assessed. We studied 420 patients (63% males, mean age 61 years), 222 received short-acting erythropoietin (EPO) and 198 long-acting darbepoetin. A total of 4654 blood samples (mean 11.1 per patient-year) were analyzed. Only 3.8% of patients were maintained within the target Hb levels (11-13 g per 100 ml) during 1 year. Hb variation events occurred in 20.8% of laboratory values and anemia events in 14.7%, with a median time to the first event of 3 months. Treatment with short-acting EPO (vs long-acting darbepoetin), change of ESA dose in the previous visit, resistance index, and hospitalization were significant risk factors for both anemia events and Hb variation events. Our results show that Hb values are rarely maintained within the recommended guidelines even in more stable hemodialysis patients. Hb variability is frequently associated with clinical events or ESA dose changes. Long-acting darbepoetin achieved better Hb stability than short-acting EPO.
authors.affiliation: Service of Nephrology, Fundación Hospital Alcorcón, Madrid, Spain. jmportoles@fhalcorcon.es
authors.forename: José M
authors.initials: JM
authors.lastname: Portolés
authors.forename: Angel L M
authors.initials: AL
authors.lastname: de Francisco
authors.forename: José L
authors.initials: JL
authors.lastname: Górriz
authors.forename: Alberto
authors.initials: A
authors.lastname: Martínez-Castelao
authors.forename: Juan M
authors.initials: JM
authors.lastname: López-Gómez
authors.forename: Manuel
authors.initials: M
authors.lastname: Arias
authors.forename: Juan J
authors.initials: JJ
authors.lastname: de la Cruz
authors.forename: Aleix
authors.initials: A
authors.lastname: Cases
authors.forename: Evaristo
authors.initials: E
authors.lastname: Fernández
authors.forename: Pedro
authors.initials: P
authors.lastname: Aljama
mesh_terms: D000328:Adult; D000368:Aged; D000740:Anemia / Q000097:blood / Q000453:epidemiology / Q000517:prevention & control; D002908:Chronic Disease; D015331:Cohort Studies; D000068256:Darbepoetin alfa; D004305:Dose-Response Relationship, Drug; D004921:Erythropoietin / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006397:Hematinics / Q000627:therapeutic use*; D006454:Hemoglobins / Q000378:metabolism*; D006801:Humans; D007674:Kidney Diseases / Q000097:blood* / Q000188:drug therapy*; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011446:Prospective Studies; D006435:Renal Dialysis; D012307:Risk Factors; D013030:Spain
chemical_list: D006397:Hematinics; D006454:Hemoglobins; D004921:Erythropoietin; D000068256:Darbepoetin alfa